Frank Watanabe

#ICYMI: Last month we announced that we raised $132.5 million in an oversubscribed #SeriesC financing to advance our pipeline of potential therapies for fibrotic lung diseases and oncology. We are thankful for the support of our investors, board, #biotech community and the entire Endeavor BioMedicines team.     In this BioSpace article, get more details about what this financing means for the future of our pipeline and our goal to restore hope for patients with life-threatening diseases: https://bit.ly/4aVqAmo    #biotechnews #fundraising #venturecapital #oncology #lungdiseases

51

David H. Crean and John Foley are thrilled to announce the creation of a new CEO Life Science peer-to-peer advisory group for San Diego CEOs with the leadership team at REF(Renaissance Executive Forum) San Diego. The focus of the REF group will be on more mature companies post-Series A funded companies including those nearing IPO’s and publicly traded companies. The new cohort is expected to begin in early 2025.   REF is a global organization that brings together business leaders in peer advisory groups to enhance their leadership skills and business strategies. Founded in the USA over 30 years ago, REF operates by assembling groups of 12 to 15 business leaders. These groups meet monthly, guided by a Forum Leader, to discuss strategic decisions and personal goals in a confidential environment. REF emphasizes the concept of "Collective Intelligence," where the diverse experiences and backgrounds of members are leveraged to foster better decision-making and personal growth. The organization serves as a hub for over 2,500 entrepreneurs, members, forum leaders, partners, ambassadors, and global speakers, providing a platform for sharing best practices and accessing new opportunities. This peer advisory model is considered more effective than traditional one-on-one coaching, as it builds lasting relationships and provides diverse perspectives that are crucial for both personal and professional development.   The partnership with REF is a recognition of the great work achieved by CEO360 with early-stage life sciences companies over the last 2.5 years plus a desire to take this platform to another level with a larger platform that REF offers for later stage companies. REF currently has a growing international footprint with an unmet need in Life Sciences well beyond the San Diego ecosystem. REF is well positioned to address those needs in 2025 and beyond.   CEO360 will stick to its core and not move away from its early-stage focus. The new REF cohort will be held in addition to the three CEO360 cohorts currently underway in San Diego, the Bay area, and via a new virtual group that will likely involve international leadership. The vision is to create a feeder program where qualified, seed-stage Life Sciences companies can benefit from the power of peer-to-peer advisory as they progress through the stages of funding - Seed, Series A, Series B, and all the way through IPO.   From a timing perspective, the new REF Life Sciences group has just started recruiting CEOs and Ambassadors in the sectors of therapeutics, pharmaceuticals, diagnostics, nutraceuticals, medical devices, and health tech.    Please stay tuned for updates as we embark on this new exciting journey and extend our mentoring support to later-stage Life Sciences CEOs. Below is a link to the REF website.    https://lnkd.in/gcgcgsBy   #Leadership #LifeSciences #CEOs #REF

16

Diakonos Oncology CFO Anthony Baldor is at #BIO24 this week to make a company presentation and meet with potential partners and investors. For those interested in learning more about Diakonos’ unique dendritic cell vaccines for cancer, we can be reached through the BIO ONE Partnering System. Mr. Baldor’s company presentation takes place on Tuesday, June 4th at 3:00 pm PT in Company Presentation Theater 2 at the San Diego Convention Center. Mr. Baldor’s presentation will include a review of Diakonos’ highly differentiated double-loaded autologous dendritic cell vaccines for cancer, and an operational update on the company’s plans for growth, including clinical development outlook and expansion of its leadership team. Diakonos recently completed a Phase 1 trial of DOC1021, its lead vaccine for glioblastoma multiforme (GBM), and is planning a Phase 2 study. The US Food and Drug Administration has granted Fast Track and Orphan Drug status for DOC1021. Two other clinical trials are under way with dendritic cell vaccines targeting pancreatic cancer and angiosarcoma. “We are very excited about the results of our Phase 1 trial for GBM,” Mr. Baldor said. “Data observed to date give us great confidence in our dendritic cell vaccines and their potential to treat a broad range of solid tumor cancers, including the most deadly. Twelve month survival is currently at 90% for evaluable patients, and the therapy is well tolerated.” Diakonos’ dendritic cell vaccines activate robust cytotoxic TH1 cell signaling pathways that better harness a patient's immune system to target and eliminate cancer cells by initiating a natural immune response. This is achieved without any genetic modification of the patient’s immune cells, which greatly simplifies the manufacturing process and significantly reduces costs when compared to leading cell therapy approaches. Visit our we site: diakonosoncology.com to learn more. #cancerresearch #cancer #biopharma #clinicaltrials https://lnkd.in/dET5pqbD

25

5 Comments

Excited for #BIO2024! Join us June 3-6 in San Diego for the year's biggest biotech gathering. Our team is ready to spark meaningful conversations and explore potential collaborations. Find us through BIO's One-on-One Partnering System https://lnkd.in/gE4y2xsy and let’s talk about advancing drug discovery for both common and rare diseases. 🤝 Meet our executive team— Helge Bastian, Steve Smith, and Wayne Vaz—at the San Diego Convention Center. We’re eager to discuss how our cutting-edge solutions are shaping the future of biotech. 👥 Industry leaders and academic partners, let’s connect and drive scientific breakthroughs together! #biotech #cellandgene #rarediseases #scientificadvancement #leadership #iXCells #innovation #ResearchCollaboration #CellTechnology #GeneTherapy #CellTherapy #DrugDiscovery #PersonalizedMedicine #RareDiseases #GeneEditing #EngineeredCells #CRISPRCas9 #CellModels #STEMCells #Biotechnology #LifeSciences #ResearchandDevelopment #motorneurons #immunecells #immunooncology #preclinicalservices

15

1 Comment

#AvalereExpert Mark Gooding moderated a panel at #BIO2024 on access and affordability considerations for patients and manufacturers in a post-#IRA world. Read highlights from his conversation with Anna Hyde, Valerie Reynolds, and Eric Gascho: https://lnkd.in/e_F3NZqM #patients #patientsupport #healthpolicy #healthcare #InflationReductionAct

21

Don't miss valuable insights from the Milken Institute's Global Conference! Larry Kessler, the Deputy Chair of the MCED Consortium, participated in a panel discussion titled "Cancer Diagnostics Revolution." The discussion focused on recent advancements in cancer screening technologies and their anticipated impact on early cancer detection, increased patient access, and effective cancer care. Esther Krofah, the US Co-Chair of the Consortium's Health Equity Workgroup, also moderated a discussion on "Prevention and Innovation for a Healthier Tomorrow," which touched on how innovation and prevention-focused strategies can lead to improved patient outcomes. Watch the sessions here: https://lnkd.in/eUuzq4RK

25